Publications by authors named "Jake McGue"

Background & Aims: The fundamental biology of pancreatic ductal adenocarcinoma has been greatly impacted by the characterization of genetically engineered mouse models that allow temporal and spatial activation of oncogenic KRAS (KRAS). One of the most commonly used models involves targeted insertion of a cre-recombinase into the Ptf1a gene. However, this approach disrupts the Ptf1a gene, resulting in haploinsufficiency that likely affects sensitivity to oncogenic KRAS (KRAS).

View Article and Find Full Text PDF
Article Synopsis
  • Immune checkpoint inhibitor (ICI) therapy shows promise for non-small cell lung cancer (NSCLC) patients with high PD-L1 expression, but not all patients respond effectively.
  • * This study uses multiplex fluorescent immunohistochemistry (mfIHC) to analyze 1,269 images from 52 metastatic NSCLC patients, identifying key interactions between tumor cells and immune cells that may predict treatment response.
  • * The research uncovers specific spatial patterns, like increased activity of cytotoxic and helper T-cells in responders, and introduces a deep learning model that identifies crucial cellular regions influencing therapy outcomes.*
View Article and Find Full Text PDF
Article Synopsis
  • Undifferentiated carcinoma (UC) and its variant, UC with osteoclast-like giant cells (UC-OGC), were compared to understand their clinical and multiomic differences, particularly in terms of survival and immunological characteristics.
  • UC-OGC was found to be more resectable and had a significantly longer median overall survival compared to UC (10.8 years vs 0.4 years), even after factoring in surgical resection.
  • Both UC and UC-OGC exhibited increased antigen-presenting cells and decreased regulatory T cells compared to pancreatic ductal adenocarcinoma (PDAC), highlighting a potential avenue for immune-modulating therapies in treating these pancreatic cancer variants.
View Article and Find Full Text PDF

Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma. Checkpoint inhibitor immunotherapy plays an essential role in management of advanced MCC; however, predictors of immunotherapy response remain poorly defined. Syngeneic mouse models suitable for testing novel immunotherapy and combination therapy approaches are likely to soon become available and will require assays for evaluating the tumor microenvironment (TME).

View Article and Find Full Text PDF
Article Synopsis
  • Pancreatic cancer is very tough to treat, with only 13% of patients surviving for five years, so better treatments are needed.
  • CD200 is a protein that can influence the immune response and is found in high amounts in pancreatic tumors, which seems to make the situation worse.
  • Scientists found that high levels of a form of CD200 in blood are linked to poorer survival rates, suggesting that targeting CD200 might help create new treatment strategies for pancreatic cancer.
View Article and Find Full Text PDF

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a 5-year survival rate of 12.5%. PDAC predominantly arises from non-cystic pancreatic intraepithelial neoplasia (PanIN) and cystic intraductal papillary mucinous neoplasm (IPMN).

View Article and Find Full Text PDF

Introduction: Metastatic colorectal cancer (mCRC) remains a common and highly morbid disease, with a recent increase in incidence in patients younger than 50 years. There is an acute need to better understand differences in tumor biology, molecular characteristics, and other age-related differences in the tumor microenvironment (TME).

Methods: 111 patients undergoing curative-intent resection of colorectal liver metastases were stratified by age into those <50 years or >65 years old, and tumors were subjected to multiplex fluorescent immunohistochemistry (mfIHC) to characterize immune infiltration and cellular engagement.

View Article and Find Full Text PDF

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is generally divided in two subtypes, classical and basal. Recently, single-cell RNA sequencing has uncovered the coexistence of basal and classical cancer cells, as well as intermediary cancer cells, in individual tumors. The latter remains poorly understood; here, we sought to characterize them using a multimodal approach.

View Article and Find Full Text PDF

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with high metastasis and therapeutic resistance. Activating transcription factor 4 (ATF4), a master regulator of cellular stress, is exploited by cancer cells to survive. Prior research and data reported provide evidence that high ATF4 expression correlates with worse overall survival in PDAC.

View Article and Find Full Text PDF

The tumor microenvironment (TME), composed of immune cells, antigens, and local soluble factors, is integral to cancer development and progression. Traditional techniques such as immunohistochemistry, immunofluorescence, or flow cytometry limit the analysis of spatial data and cellular interactions within the TME, as they are restricted to colocalization of a small number of antigens or the loss of tissue architecture. Multiplex fluorescent immunohistochemistry (mfIHC) allows for detection of multiple antigens within a single tissue sample, providing a more comprehensive description of tissue composition and spatial interactions within the TME.

View Article and Find Full Text PDF

Unlabelled: The adult healthy human pancreas has been poorly studied given the lack of indication to obtain tissue from the pancreas in the absence of disease and rapid postmortem degradation. We obtained pancreata from brain dead donors, thus avoiding any warm ischemia time. The 30 donors were diverse in age and race and had no known pancreas disease.

View Article and Find Full Text PDF

Unlabelled: The adult healthy human pancreas has been poorly studied given lack of indication to obtain tissue from the pancreas in the absence of disease and rapid postmortem degradation. We obtained pancreata from brain dead donors thus avoiding any warm ischemia time. The 30 donors were diverse in age and race and had no known pancreas disease.

View Article and Find Full Text PDF

Despite advances in therapy over the past decades, metastatic colorectal cancer (mCRC) remains a highly morbid disease. While the impact of MHC-I on immune infiltration in mCRC has been well studied, data on the consequences of MHC-II loss are lacking. Multiplex fluorescent immunohistochemistry (mfIHC) was performed on 149 patients undergoing curative intent resection for mCRC and stratified into high and low human leukocyte antigen isotype DR (HLA-DR) expressing tumors.

View Article and Find Full Text PDF